Kundu S K, Katzenstein D, Valentine F T, Spino C, Efron B, Merigan T C
Center for AIDS Research at Stanford, Stanford University Medical Center, California 94305, U.S.A.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 1;15(4):269-74. doi: 10.1097/00042560-199708010-00004.
Therapeutic vaccination has been proposed as a strategy to augment immune mechanisms to control viral replication and slow clinical progression of HIV infection to disease. Following recombinant gp160 (r-gp160) immunization in three clinical trials, plasma HIV-1 RNA and cellular proviral DNA were assessed by quantitative polymerase chain reaction (PCR) in 76 HIV-seropositive subjects with CD4+ T cell counts > or = 300/mm3. Immunization increased HIV-specific cellular immune responses (e.g., cytotoxic T lymphocyte [CTL] activities, lymphocyte proliferative responses); however, there were no significant effects of immunization or cellular immune responses on measures of plasma RNA or cellular DNA viral load.
治疗性疫苗接种已被提议作为一种增强免疫机制的策略，以控制病毒复制并减缓HIV感染向疾病的临床进展。在三项临床试验中对重组gp160（r-gp160）进行免疫接种后，通过定量聚合酶链反应（PCR）对76名CD4+T细胞计数≥300/mm3的HIV血清阳性受试者的血浆HIV-1 RNA和细胞原病毒DNA进行了评估。免疫接种增强了HIV特异性细胞免疫反应（例如，细胞毒性T淋巴细胞[CTL]活性、淋巴细胞增殖反应）；然而，免疫接种或细胞免疫反应对血浆RNA或细胞DNA病毒载量的测量没有显著影响。
